H.C. Wainwright Starts SteadyMed (STDY) at Buy; Sees High Likelihood of IPR Ruling in Favor of Company
Tweet Send to a Friend
H.C. Wainwright initiates coverage on SteadyMed (NASDAQ: STDY) with a Buy rating and a price target of $10.00.Analyst Andrew Fein ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
